Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best ...
Alvin Chan / SOPA Images / LightRocket via Getty Images Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials. Abbvie said ...
By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ...
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug. AbbVie ABBV shares are down 12.4%. In a statement ...
Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part ...
Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very ...
Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia ...
AbbVie shares, which hit a 52-week high in late October after the drugmaker posted quarterly earnings that topped Wall Street's expectations and raised its dividend by nearly 6%, were recently down ...
In trading on Monday, shares of AbbVie crossed below their 200 day moving average of $178.81, changing hands as low as $172.70 per share.
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AbbVie shares tumbled more than 10 per cent on Monday, wiping more than $30bn from the drugmaker’s market value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback